Aim: Sarcopenia, the loss of skeletal muscle mass, impairs prognosis of patients with liver cirrhosis. The aim of this study was to investigate the effect of loop diuretics, which are frequently used to treat hepatic edema/ascites, on skeletal muscle depletion and the prognosis in patients with liver cirrhosis.
INTRODUCTION

S
ARCOPENIA, THE LOSS of skeletal muscle mass, is part of the normal aging process in an elderly population. It is also associated with various diseases, including heart failure, chronic kidney disease, inflammatory bowel disease, cognitive impairment, and cancers. 1 Furthermore, sarcopenia is observed in 40-70% of patients with liver cirrhosis, depending on the diagnostic criteria. [1] [2] [3] Sarcopenia has been shown to associate with adverse clinical outcomes, such as lower survival rate, poor quality of life, physical disability, increased risk of developing hepatic encephalopathy and infections, and lower post-liver transplantation survival. [3] [4] [5] [6] Several studies have also reported that sarcopenia is an independent prognostic factor in patients with liver cirrhosis, regardless of the presence or stage of hepatocellular carcinoma. [7] [8] [9] [10] Time-course changes in body composition characterized by loss of skeletal muscle mass are frequently observed in patients with liver cirrhosis. 11 The physiological skeletal muscle loss in normal aging is approximately 1%/year up to age 70 years, increasing later to 1.5%/year. 12 In our previous study, we revealed that an annual ratio of skeletal muscle loss is twofold faster in patients with liver cirrhosis than in healthy people, indicating that cirrhosis accelerates loss of skeletal muscle mass in these patients. 13 In addition, we found that more rapid skeletal muscle loss (>3.1%/year) raises the risk of mortality, independently of the severity of liver disease. 13 Therefore, identifying risk factors associated with skeletal muscle depletion is necessary for the management of patients with liver cirrhosis.
Multiple mechanisms, such as increase in ammonia, decrease in testosterone and growth hormone, imbalance between protein synthesis and breakdown, changes in
METHODS
Patients
I
N THIS RETROSPECTIVE study, we reviewed the clinical records of 226 patients with liver cirrhosis who had been treated in Gifu University Hospital (Gifu, Japan) between March 2004 and June 2017. The diagnosis of cirrhosis was made on the basis of clinical data, including liver biopsy specimens, laboratory tests, clinical features of portal hypertension, and/or medical imaging such as computed tomography (CT). We examined the following data in each patient: clinical characteristics and laboratory tests, severity of liver disease, prescription and dosage of loop diuretics and aldosterone antagonist, branched-chain amino acid (BCAA) supplementation, and time-course changes in skeletal muscle area per year (ΔSMA [%]). Branched-chain amino acid supplementation comprised the BCAA-enriched powder mix (Aminoleban EN powder mix; Otsuka Pharmaceutical, Tokyo, Japan) or BCAA granules (LIVACT Granules; EA Pharma, Tokyo, Japan). We compared the differences in clinical outcomes between patients treated with loop diuretics at 20 mg or less/day (≤20 mg) and those treated with more than 20 mg/day (>20 mg). Skeletal muscle area was evaluated using the cross-sectional area on CT imaging in each patient because most patients with liver cirrhosis had surveillance CT scans for hepatocellular carcinoma, vascular disease, and pretransplant evaluation.
The exclusion criteria were as follows: bed rest, sedentary lifestyle, presence of inflammatory disease, presence of hepatocellular carcinoma or other known malignancy, severe endocrine disease, active ongoing infections, presence of neurological diseases such as Parkinson's disease, presence of gastrointestinal disorders or use of medications that cause anorexia, and the presence of advanced organ failure (heart, lung, kidney, and brain).
The purpose of each examination was completely explained, and informed consent was obtained from all participants. The study protocol was approved by the ethics committee of Gifu University Graduate School of Medicine (approval no. #29-328) and was carried out in accordance with the 1975 Declaration of Helsinki.
Evaluation of change in SMA
The cross-sectional area of the skeletal muscles (cm 2 ) was evaluated on CT imaging at the level of the third lumbar vertebra (L3). The skeletal muscles at this L3 level consist of the psoas, erector spinae, quadratus lumborum, transversus abdominis, internal oblique, external oblique, and rectus abdominis. This cross-sectional area of the skeletal muscles provides a significant estimate of the whole-body muscle mass. Decrease in this muscle area is associated with lower survival rate in patients with liver cirrhosis independent of both Child-Pugh scores and Model for End-Stage Liver Disease (MELD) scores. 9 The L3 cross-sectional area of the skeletal muscles was measured on CT imaging with image analysis software (sliceOmatic V4.3; TomoVision, Magog, Canada), which enables specific tissue demarcation using Hounsfield units. This area was identified and quantified by Hounsfield unit thresholds of À29 to +150. 20 We calculated ΔSMA as follows: ΔSMA (%) = (SMA at final CT scan -SMA at initial CT scan) / SMA at initial CT scan × 100 / interval between CT scans (years). 13 
Clinical characteristics and laboratory tests
Clinical characteristics and laboratory parameters were collected within 2 weeks of the initial CT scan in each patient. The weight and height were measured, and the body mass index (BMI, kg/m 2 (Diacolor BTR; Toyobo, Osaka, Japan). The severity of liver disease was assessed by both the Child-Pugh classification and the MELD score in each patient within 2 weeks of the initial CT scans.
Statistical analysis
Continuous variables are presented as median and interquartile range (IQR), and categorical variables are shown as number of patients and percentages (%). We used the Mann-Whitney U-test to evaluate the significance of the differences in the distribution of continuous variables and the χ 2 -test to compare the proportions of categorical variables between the groups. Correlations between ΔSMA and the other parameters at baseline were analyzed using Spearman's rank correlation coefficient. Multivariate linear regression analysis was used to identify the independent predictors of ΔSMA. Data were censored on 30 June 2017.
Propensity score matching was used to reduce the effects of selection bias and of potential confounding on measured outcomes as a result of differences in baseline characteristics between patients treated with loop diuretics >20 mg/day and those treated with ≤20 mg/day. This score was calculated using a logistic regression model and variables included in the model were age, sex, BMI, etiology, albumin, total bilirubin, and INR. This model yielded a c-index of 0.76. After propensity scores were estimated, one-to-one nearest-neighbor matching without replacement was undertaken with a caliper of width equal to 0.2 of the standard deviation of the logit of the propensity score.
Patients who were lost to follow-up were censored at the data of last contact/follow-up. Patients who were alive on 30 June 2017 were censored for overall survival analysis. The cumulative survival rates were estimated with the Kaplan-Meier method, and compared between groups by the log-rank test. Univariate and multivariate analyses were carried out using the Cox proportional hazards regression model to identify risk factors for mortality. All statistical analyses were undertaken using JMP version 13.0 (SAS Institute, Cary, NC, USA). The significance threshold was set at 0.05.
RESULTS
Patient characteristics
T ABLE 1 SHOWS THE baseline clinical characteristics and laboratory data of the patients. This retrospective study included 226 patients (137 men and 89 women) with a median age of 64 years (IQR, 55-71). The etiology of liver cirrhosis included hepatitis B virus infection (n = 18), hepatitis C virus infection (n = 105), alcohol intake (n = 64), primary biliary cholangitis (n = 14), autoimmune hepatitis (n = 4), non-alcoholic steatohepatitis (n = 3), and cryptogenic cirrhosis (n = 18). The median Child-Pugh score was 6 (IQR, [5] [6] [7] [8] , and the median MELD score was 9 (IQR, 7-11). The numbers of patients in Child-Pugh classes A, B, and C were 119 (53%), 73 (32%), and 34 (15%), respectively. The number of patients given BCAA supplementation was 89 (58 for BCAA granules and 31 for BCAA-enriched powder mix). In this study, 79 (35%) patients were treated with loop diuretics (69 for furosemide and 10 for azosemide), and 70 patients (31%) received aldosterone antagonist (all spironolactone). None of the patients was treated with tolvaptan during the follow-up period.
The median interval from the initial CT to the final CT scan was 35 months (IQR, 14-58). The median ΔSMA in all patients was À3.0% (IQR, À9.6 to À0.2). The median ΔSMA was À3.8% (IQR, À7.5 to À1.5) in loop diuretic alone (n = 21), À5.6% (IQR, À10.4 to À1.6) in aldosterone antagonist alone (n = 11), and À5.1% (IQR, À19.3 to À0.8) in the combination of loop diuretic and aldosterone antagonist (n = 59). During the follow-up period, skeletal muscle depletion was observed in 174 (77%) patients. The comparison of the clinical characteristics between patients with ΔSMA of À3.1% or less (≤ À3.1%, n = 111) and those of more than À3.1% (> À3.1%, n = 115), which value best predicted the mortality of patients with liver cirrhosis in the previous study, 13 is shown in Table 1 . The numbers of patients with BCAA supplementation (P = 0.024), loop diuretic treatment (P < 0.001), and aldosterone antagonist treatment (P < 0.001) were significantly higher in patients with ΔSMA ≤ À3.1% than in those with ΔSMA > À3.1%. The Child-Pugh score was also significantly higher in patients with ΔSMA ≤ À3.1% than in those with ΔSMA > À3.1% (P < 0.001); by contrast, the serum albumin levels (P = 0.002), serum sodium levels (P = 0.001), and serum chloride levels (P = 0.006) were lower in patients with ΔSMA ≤ À3.1% than in those with ΔSMA > À3.1%. No significant difference was found in age, sex, BMI, the etiology of liver cirrhosis, or serum ammonia, serum creatinine, estimated glomerular filtration rate, serum creatine kinase, serum lactate dehydrogenase, or serum aspartate transaminase levels between the two groups.
Comparison of clinical characteristics of the patients divided by the dosage of loop diuretics (≤20 mg/day or >20 mg/day) is summarized in Table 2 . Among the patients, 39 (17%) were treated with loop diuretics >20 mg at the time of the entry. The numbers of patients with BCAA supplementation, loop diuretic treatment, and aldosterone antagonist treatment were significantly higher in patients who received loop diuretics >20 mg than in those treated with ≤20 mg (P < 0.0001, respectively). The ChildPugh score (P < 0.0001), MELD score (P < 0.0001), INR values (P = 0.013), serum creatinine levels (P = 0.038), and serum lactate dehydrogenase levels (P = 0.002) were significantly higher, but serum albumin levels (P < 0.0001), serum sodium levels (P = 0.001), serum chloride levels (P = 0.005), and serum aspartate transaminase levels (P = 0.046) were significantly lower in patients treated with loop diuretics >20 mg than in treated with ≤20 mg. The median ΔSMA in patients who received loop diuretics >20 mg and in those who received ≤20 mg was À5.4% and À2.3% (P = 0.017), respectively. After the 1:1 propensity score-matching analysis, 38 cirrhotic patients were identified in each group. Among propensity-matched patients, no significant difference was found in clinical characteristics or laboratory variables between patients treated with loop diuretics >20 mg and those at ≤20 mg; however, the median ΔSMA was significantly lower in patients with loop diuretics >20 mg than in those treated with ≤20 mg (À5.7% vs. À2.2%; P = 0.033). Therefore, the patients with liver cirrhosis treated with higher doses of loop diuretics showed a more rapid decrease in skeletal muscle mass. Significant factors that affect SMA in patients with liver cirrhosis Table 3 shows the correlation coefficient between ΔSMA and candidate parameters. The factor directly correlated with ΔSMA was serum albumin levels, serum sodium levels, and serum chloride levels, and those inversely correlated with ΔSMA were loop diuretic treatment, aldosterone antagonist treatment, Child-Pugh score, MELD score, total bilirubin levels, and serum lactate dehydrogenase levels. ‡Statistical analysis was carried out using the χ No significant correlation was found between ΔSMA and other parameters including age, sex, BMI, BCAA supplementation, INR values, or serum ammonia, serum creatinine, estimated glomerular filtration rate, serum potassium, serum creatine kinase, or serum aspartate transaminase levels. Multivariate analysis found that loop diuretic treatment was significantly associated with ΔSMA (model 1, t = À3.07, P = 0.002; model 2, t = À3.18, P = 0.002; model 3, t = À3.07, P = 0.002). Severe hepatic fibrosis is widely accepted as a risk factor for skeletal muscle depletion; 21 however, no significant correlation was observed between ΔSMA and the Fibrosis-4 index, a useful hepatic fibrosis marker, in the present study (r = À0.04, P = 0.55).
Survival rates of patients with liver cirrhosis
Patients were followed up for a median of 49 months (IQR, 25-71). During the follow-up period, 82 (36%) patients died. Of these patients, 19 patients were treated with loop diuretics >20 mg (19/39, 48%) and 63 patients received ≤20 mg (63/187, 34%). The causes of death consisted of liver failure (n = 52), hepatocellular carcinoma (n = 13), sepsis (n = 5), gastrointestinal bleeding (n = 2), and other reasons (n = 10). Overall survival rates were significantly lower in patients treated with loop diuretics >20 mg than in those treated with ≤20 mg (median, 66 months vs. 97 months; P = 0.002; Fig. 1a) . The 2-, 4-, 6-, 8-, and 10-year survival rates in patients treated with loop diuretics >20 mg were 77%, 64%, 31%, 23%, and 0%, respectively; by contrast, those in patients who received ≤20 mg were 91%, 80%, 61%, 48%, and 32%, respectively. No significant difference was found in survival rates between patients with aldosterone antagonist ≤25 mg and those treated with >25 mg (P = 0.49, Fig 1b) . Overall survival rates in patients with MELD score ≥10 were significantly lower than the survival rates in those with a score <10 (P = 0.049, Fig 1c) . Similarly, the survival rates in patients with ΔSMA ≤ À3.1% were significantly 
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lower than the survival rates in those with ΔSMA > À3.1% (P < 0.0001, Fig 1d) . The frequency of hepatic encephalopathy development, which impacts quality of life, was significantly higher in patients with ΔSMA ≤ À3.1% than in those with ΔSMA > À3.1% (P = 0.037).
We then evaluated the impact of ΔSMA provided by the short observation period of the onset of disease (median interval, 7.7 months; IQR, 5.0-12.7) on the prognosis of cirrhotic patients. In this analysis, the median ΔSMA was À0.1% (IQR, À10.5 to 9.6%) and the survival rates were also significantly lower in patients with ΔSMA ≤ À3.1% than in those > À3.1% (P < 0.001). These findings might suggest that rapid decrease of skeletal muscle observed in the incipient disease phase might also predict the prognosis of patients with liver cirrhosis.
In addition, we compared the survival rates in each Child-Pugh class between patients treated with loop diuretics >20 mg and those treated with ≤20 mg. The survival rates in the Child-Pugh classes A (P = 0.042, Fig. 2a) and B (P = 0.049, Fig. 2b) were significantly lower in patients treated with loop diuretics >20 mg than in those treated with ≤20 mg. However, in the Child-Pugh class C patients, no significant difference was found in the survival rates between the two groups (P = 0.63, Fig 2c) .
Prognosticfactorsofpatientswithlivercirrhosis
We performed univariate and multivariate Cox proportional hazards model analyses to identify the risk factors associated with poor prognosis in patients with liver cirrhosis (Table 4) . Univariate analysis showed significant differences in terms of loop diuretic treatment (>20 mg), etiology of cirrhosis, Child-Pugh class C, and ΔSMA (≤ À3.1%). Multivariate analysis revealed that loop diuretics at >20 mg (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.03-3.24; P = 0.039), etiology of cirrhosis, and ΔSMA of ≤ À3.1% (HR, 3.87; 95% CI, 2.32-6.60; P < 0.0001) were associated with an increased risk of all-cause mortality in patients with liver cirrhosis. With reference to hepatitis B virus patients, the HRs of mortality in hepatitis C virus infection, alcohol intake, and other were 7.48 (95% CI, 2.22-46.62; P < 0.001), 6 .68 (95% CI, 1.86-42.76; P = 0.002), and 7.87 (95% CI, 2.07-51.80; P = 0.001), respectively. No significant difference was found in serum sodium levels (≤135 mEq/L) in the univariate (HR, 1,76; 95% CI, 0.90-3.16; P = 0.10) or multivariate analyses (model 2: HR, 1,16; 95% CI, 0.55-2.30; P = 0.68).
Serum BTR values were available in 133 patients with liver cirrhosis (59%), and the median BTR value was 3.6 (IQR, 2.6-4.9). We undertook a multivariate analysis including serum BTR values to identify the prognostic factors (Table 5 ). Multivariate analysis revealed that BTR of ≤3.5 (HR, 2.69; 95% CI, 1.22-6.42; P = 0.013) was associated with mortality in patients with liver cirrhosis, as well as loop diuretics at >20 mg (HR, 3.12; 95% CI, 1.27-7.24; P = 0.015), etiology of cirrhosis (hepatitis C virus infection; Figure 2 Overall survival rates in each Child-Pugh class between patients with liver cirrhosis treated with loop diuretics at doses >20 mg and those at doses ≤20 mg. (a) Child-Pugh A patients (n = 119). (b) Child-Pugh B patients (n = 73). (c) Child-Pugh C patients (n = 34). Overall survival rates in Child A patients (P = 0.042) and Child B patients (P = 0.049) were significantly lower in patients treated with loop diuretics >20 mg versus ≤20 mg. However, in Child C patients, no significant difference was found in survival rates between the two groups (P = 0.63).
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Hepatology Research 2019; 49: 82-95 HR, 4.10; 95% CI, 1.08-27.09; P = 0.037), and ΔSMA of ≤ À3.1% (HR, 4.29; 95% CI, 2.01-9.70; P < 0.001). No significant difference was found in serum sodium levels (≤135 mEq/L) in the univariate (HR, 1,41; 95% CI, 0.52-3.18; P = 0.47) or multivariate analysis (model 2: HR, 1,51; 95% CI, 0.51-3.93; P = 0.43).
DISCUSSION
T O THE BEST of our knowledge, this study is the first to examine the association between loop diuretic treatment and skeletal muscle depletion in patients with liver cirrhosis. The results of the present study clearly showed 0.6800 †Model 1 adjusted for age, gender, loop diuretics, etiology of cirrhosis, Child-Pugh class, Model for End-stage Liver Disease (MELD) score, and change in skeletal muscle area per year (ΔSMA). ‡Model 2 adjusted for all variables in model 1 plus sodium (Na). BCAA, branched-chain amino acid; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio. Loop diuretics and muscle in cirrhosis 91 Hepatology Research 2019; 49: 82-95 that a higher dose of loop diuretic treatment was associated with a more rapid decrease of skeletal muscle mass in patients with liver cirrhosis, independent of the severity of liver disease, suggesting that loop diuretic use is one of the critical risk factors of sarcopenia. We also found that loop diuretic treatment, ΔSMA, and BTR were significant risk factors for poor survival, independent both of the Child-Pugh class and MELD score in patients with liver cirrhosis. These results have clinical significance because loop diuretics, which are one of the commonly prescribed drugs for patients with liver cirrhosis with hepatic edema and/or ascites, could decrease skeletal muscle mass, which worsens the prognosis of these patients. Therefore, careful consideration of the risk of sarcopenia might be necessary when using high doses of loop diuretics in patients with liver cirrhosis.
Skeletal muscle mass is maintained by a balance among protein synthesis, protein breakdown, and muscle regenerative capacity. Multiple mechanisms are involved in the skeletal muscle loss or sarcopenia in patients with liver cirrhosis. 3 Mandai et al. 18 have recently revealed that loop diuretics impair skeletal myoblast differentiation and exercise-induced muscle hypertrophy by inhibiting the function of Na
À cotransporter 1 (NKCC1), which is highly expressed in skeletal muscle. Several studies have shown that NKCC, which aids in the active transport of Na, K, and Cl into cells, plays an essential role in skeletal myogenesis. 22, 23 Another member of NKCC family, NKCC2, is a major target of loop diuretics in the kidney. The results of these study could suggest that loop diuretics are involved in the loss of skeletal muscle mass and development of sarcopenia. 18, 22, 23 Therefore, sarcopenia in patients with liver cirrhosis might be attributable to treatment with loop diuretics, and the findings of these basic studies, 18, 22, 23 together with the results of our clinical study, could support this hypothesis.
The results of the present study also showed that a higher dose of loop diuretics was associated with lower survival rate, independent both of skeletal muscle depletion and liver function reserves. Long-term treatment with loop diuretics sometimes induces adverse events, including hyponatremia and renal impairment, both of which are independent risk factors for mortality in patients with liver cirrhosis. 16 Tolvaptan, a selective vasopressin V2 receptor antagonist with an aquaretic effect, is effective in the treatment of patients with volume overload and is not associated with electrolyte imbalance and/or renal impairment. [24] [25] [26] Early treatment with this agent, instead of increasing the dose of loop diuretics, reduces the incidence of renal impairment in patients with liver cirrhosis with ascites. 27 Taken together, an early tolvaptan add-on therapy to refrain from using high-dose loop diuretics could contribute in preventing skeletal muscle loss and in raising the survival rate in patients with liver cirrhosis, although further study is required to clarify this possibility. The major strategies that are expected to increase skeletal muscle mass in patients with liver cirrhosis include BCAA supplementation and increased physical activity. 3 Branched-chain amino acid supplementation is one of the main therapeutic options to prevent skeletal muscle depletion because BCAA provides not only a source of energy to the muscle but also substrates for protein synthesis. [28] [29] [30] [31] However, no statistical significance was found between ΔSMA and BCAA supplementation (P = 0.19), nor serum BTR values (P = 0.15), in the present study. A prospective study investigated the long-term effect of BCAA supplementation on skeletal muscle mass of patients with liver cirrhosis, although skeletal muscle mass tended to decrease during the 48-week observation period. 32 By contrast, BCAA supplementation together with moderate physical exercise can be effective to increase skeletal muscle mass in patients with liver cirrhosis. 33, 34 Therefore, these results indicate that cirrhosis can be seen as a state of anabolic resistance, and BCAA supplementation alone seems to be inadequate to increase skeletal muscle mass in patients with liver cirrhosis.
Hyperammonemia, which is a consistent abnormality in cirrhosis due to impaired ureagenesis and portosystemic shunting, is also one of the key mechanisms of skeletal muscle depletion and, therefore, ammonia-lowering treatment might be an effective approach for sarcopenia prevention. 3 Hyperammonemia in cirrhosis induces transcriptional upregulation of myostatin, an inhibitor of protein synthesis and potentially an activator of proteolysis, and contributes to sarcopenia through the mechanisms of impaired protein synthesis and increased autophagy. 3 A study in a model of sarcopenia in cirrhosis with hyperammonemia has revealed that ammonia-lowering strategies result in partial reversal of muscle loss and recovery of protein synthesis rates, both of which reverse sarcopenia of cirrhosis; 35 however, no significant correlation was found between serum ammonia levels and ΔSMA in the present study. This reason can be attributed to the fact that 35% (79/226) of patients received ammonialowering therapy during the follow-up period.
This study has several limitations. First, it was a retrospective and single-center study. Second, both dietary intake and daily physical activity have been shown to be associated with skeletal muscle depletion and mortality in patients with liver cirrhosis, 36 although these data were unavailable due to the study's retrospective design. Finally, dose and duration of loop diuretic treatment during the follow-up period was decided by the attending physicians. This resulted in significant differences in baseline characteristics between patients treated with loop diuretics >20 mg and those treated with ≤20 mg, and could exert an influence on the results of the present study, even though propensity score-matching analysis and multivariate analysis were undertaken to reduce the selection bias and potential confounding.
The results of the present study showed an urgent need for strategic change of the treatment of hepatic edema and/or ascites in clinical practice. Namely, using a high dose of loop diuretics should be avoided and early tolvaptan add-on therapy should be adopted to prevent sarcopenia in patients with liver cirrhosis. Protection of renal function and prevention of sarcopenia by decreasing the dose of loop diuretics could improve the prognosis of patients with liver cirrhosis suffering from edema/ascites. 26 In addition, it should be reconsidered that cirrhotic patients with ascites are liable to sarcopenia because pathophysiological conditions observed in ascites, such as activation of the renin-angiotensin system, are critically involved in loss of skeletal muscle mass. 37 Therefore, it goes without saying that maintaining liver function reserve, which prevents hypoalbuminemia as well as ascites, is a first step to improving sarcopenia.
In conclusion, we found that a higher dose of loop diuretic treatment was associated with more rapid skeletal muscle depletion and an increased risk of mortality, independent of the severity of liver disease. These results raise the important possibilities that refraining from high-dose loop diuretics for the treatment of hepatic edema and/or ascites might contribute to preventing skeletal muscle depletion and improving the prognosis of patients with liver cirrhosis. Further prospective study is required to examine the effect of loop diuretics on skeletal muscle depletion with more patients and a longer follow-up period.
